Metrics as of 10/14/2026, 07:21 PM (Berlin time), refresh in progress.
Oruka Therapeutics Stock
Oruka Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lawrence Otto Klein
- Employees
- 68
- Market cap
- $5.1 B
- IPO
- 08/08/1997
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California. The company focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001, which targets the p19…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Oruka Therapeutics stock: price history
1D
-1.9%
1W
-3.5%
1M
-20.1%
6M
+17.0%
YTD
+153.0%
1Y
+179.0%
2Y
+176.4%
5Y
+129.0%
10Y
-85.6%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~47% weaker price swings than usual
Oruka Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment of psoriasis and other inflammatory and immunological diseases. The company maintains a pipeline of various drug candidates, including ORKA-001 (Phase 2a) targeting interleukin-23, ORKA-002 (Phase 2) targeting interleukin-17A/F, as well as additional research approaches such as drug combinations to optimize therapeutic outcomes.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Oruka Therapeutics
Analyst assessment of Oruka Therapeutics
PRICE TARGET LOW
US$120.00
CONSENSUS
US$144.56
MEDIAN
US$130.00
PRICE TARGET HIGH
US$200.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 24/09/2026
Oruka Therapeutics stock metrics
P/E
-31.04
P/B
4.33
EV/EBITDA
-33.96
RETURN ON EQUITY
-3.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.2%
FLOAT SHARES
50,803,656
AVG. DAILY VOLUME (30D)
936,561
Insider transactions (SEC)
Goncalves Joana
Goncalves Joana
Goncalves Joana
Goncalves Joana
Goncalves Joana
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Oruka Therapeutics stock
What does Oruka Therapeutics do?
Oruka Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lawrence Otto Klein, the company employs around 68 people.
The IPO was on 08/08/1997; the stock trades on NASDAQ under the ticker ORKA.
What do analysts say about Oruka Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$144.56, ranging from US$120.00 to US$200.00, with a median of US$130.00.
This is an external assessment, not a statement by Market Jury.
When does Oruka Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -47% stronger than usual.
Does Oruka Therapeutics pay a dividend?
Yes. The last dividend was US$1.61 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Oruka Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Oruka Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oruka Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.